Your browser doesn't support javascript.
loading
A single-center, open-label study investigating the excretion balance, pharmacokinetics, metabolism, and absolute bioavailability of a single oral dose of [14C]-labeled idasanutlin and an intravenous tracer dose of [13C]-labeled idasanutlin in a single cohort of patients with solid tumors.
Pápai, Zsuzsanna; Chen, Lin-Chi; Da Costa, Daniel; Blotner, Steven; Vazvaei, Faye; Gleave, Michelle; Jones, Russell; Zhi, Jianguo.
Afiliação
  • Pápai Z; PRA Magyarország Kft, Fázis I-es Klinikai Farmakológiai Vizsgálóhely, Budapest, Hungary.
  • Chen LC; Roche Innovation Center of New York, New York, NY, USA.
  • Da Costa D; Roche Innovation Center of New York, New York, NY, USA.
  • Blotner S; Roche Innovation Center of New York, New York, NY, USA.
  • Vazvaei F; Roche Innovation Center of New York, New York, NY, USA.
  • Gleave M; York Bioanalytical Solutions, Sandwich, UK.
  • Jones R; Roche Innovation Center of Basel, Basel, Switzerland.
  • Zhi J; Roche Innovation Center of New York, New York, NY, USA. jianguo.zhi8@gmail.com.
Cancer Chemother Pharmacol ; 84(1): 93-103, 2019 07.
Article em En | MEDLINE | ID: mdl-31062077
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pirrolidinas / Proteínas Proto-Oncogênicas c-mdm2 / Para-Aminobenzoatos / Neoplasias / Antineoplásicos Idioma: En Ano de publicação: 2019 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pirrolidinas / Proteínas Proto-Oncogênicas c-mdm2 / Para-Aminobenzoatos / Neoplasias / Antineoplásicos Idioma: En Ano de publicação: 2019 Tipo de documento: Article